Patent application number | Description | Published |
20130030357 | SYSTEM AND METHOD FOR PAIRING A DIALYSIS MACHINE WITH PERIPHERAL DEVICES - A dialysis system includes: a dialysis machine; and at least one of a blood pressure sensor and a weight sensor in wireless communication with the dialysis machine, wherein the dialysis machine is so positioned and arranged relative to the at least one blood pressure sensor or weight sensor that the dialysis machine is discoverable by the at least one blood pressure sensor or weight sensor when the at least one blood pressure sensor or weight sensor, respectively, is powered, and such that the at least one blood pressure sensor or weight sensor becomes paired automatically with the dialysis machine for secure wireless communication. | 01-31-2013 |
20130037461 | CUSTOMIZABLE PERSONAL DIALYSIS DEVICE HAVING EASE OF USE AND THERAPY ENHANCEMENT FEATURES - A peritoneal dialysis machine includes an enclosure; dialysate pump located within the enclosure; a graphical user interface allowing a patient to program a treatment including at least one patient fill performed by the dialysate pump, at least one dwell, and at least one drain performed by the dialysate pump; and the GUI further programmed to provide an alert when it is time to begin the treatment so as to complete the at least one patient fill, dwell and drain by a prescribed time. | 02-14-2013 |
20130071906 | CELL CULTURE MEDIUM FOR ADAMTS PROTEIN EXPRESSION - The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein. | 03-21-2013 |
20130078264 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 03-28-2013 |
20130079704 | DIALYSIS METHOD INCLUDING WIRELESS PATIENT DATA - A dialysis method comprising coding a wireless receiver of a dialysis machine with at least one of an address or a personal identification number (“PIN”); and receiving at least one of blood pressure data from a blood pressure monitor wirelessly or patient weight data from a weight scale wirelessly, wherein the at least one coded address or PIN ensures that the at least one of the blood pressure data or the patient weight data is received by the receiver as opposed to a receiver of another dialysis machine. | 03-28-2013 |
20130079705 | METHOD FOR MONITORING AND CONTROLLING PERITONEAL DIALYSIS - A dialysis apparatus includes a housing; a first electrical contact carried by the housing; a hydrogel material located within the housing; a second electrical contact connected to the hydrogel material, the hydrogel material located so as to be contacted by a liquid flowing through the housing; and wherein the hydrogel material expands as the material absorbs the liquid such that the second electrical contact is moved and eventually engage the first electrical contact. | 03-28-2013 |
20130079706 | DIALYSIS SYSTEM HAVING DISPOSABLE CASSETTE - A dialysis system includes a dialysis instrument and a disposable cassette. The dialysis instrument includes three pump actuators. The disposable cassette includes three dialysate pump chambers. The three dialysate pump chambers are positioned and arranged to operate with the three dialysate pump actuators of the dialysis instrument. | 03-28-2013 |
20130079710 | Therapy Management Development Platform - A therapy management development platform includes a pump controller coupled to an interface module. The interface module includes an interface module controller and a module-sensor input/output interface including at least one standardized input port, output port and power connection. The interface module is also customizably programmed to receive data from a sensor and to provide instructions to the pump controller to vary the operation of a pump coupled thereto according to one of a plurality of levels of functionality. Upon receipt of an indication of approval from a remote computer to change the level of access to the functionality of the platform, the interface module may be customizably programmed to receive different data from the sensor, to provide different instructions to the pump controller, or both, the approval corresponding to a stage in testing of a medical device. | 03-28-2013 |
20130090291 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 04-11-2013 |
20130096062 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 04-18-2013 |
20130096063 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 04-18-2013 |
20130096082 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition composing chitin or a water insoluble chitin derivative, especially water insoluble chitosan, in particulate form, wherein the composition is present in paste form. | 04-18-2013 |
20130096480 | ACCESS DISCONNECTION SYSTEMS WITH ARTERIAL AND VENOUS LINE CONDUCTIVE PATHWAY - An extracorporeal blood system includes: an extracorporeal blood machine; an arterial line extending from the extracorporeal blood machine; a venous line extending from the extracorporeal blood machine; and an access disconnection circuit for detecting a disconnection of at least one of the arterial or venous lines from a patient, the access disconnection circuit including (i) a signal generation source having first and second signal generation source electrical lines each in electrical communication with blood traveling through one of the arterial or venous lines, (ii) a conductive pathway electrically communicating blood traveling through the arterial line with blood traveling through the venous line, and (iii) a signal processing unit positioned and arranged to process a signal generated by the source to detect the disconnection of the at least one of the arterial and venous lines. | 04-18-2013 |
20130096481 | SYSTEMS AND METHODS FOR OPTICAL ACCESS DISCONNECTION - An access disconnection system includes: a material capable of absorbing blood from a patient, a light emitter positioned to emit light onto a first portion of the material, the first portion spaced at least a threshold distance from a second portion of the material, the second portion located so as to cover arterial line and venous line access points to the patient, the threshold distance including a distance from the access points to provide for an allowable amount of blood seepage from either access point due to a needle stick, a receiver positioned adjacent to the light emitter to receive light reflected off of the first portion of the material, and circuitry coupled to the light emitter and receiver and configured to provide an output (i) when light received by the receiver reaches a particular level or (ii) indicative of an amount of light received by the receiver. | 04-18-2013 |
20130101579 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 04-25-2013 |
20130102537 | MANUFACTURE OF FACTOR H (FH) AND FH-DERIVATIVES FROM PLASMA - The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction. | 04-25-2013 |
20130115204 | PREPARATIVE PURIFICATION PROCESS FOR HUMAN FURIN - Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%. | 05-09-2013 |
20130119265 | METHODS FOR THE INACTIVATION OF MIRCROORGANISMS IN BIOLOGICAL FLUIDS, FLOW THROUGH REACTORS AND METHODS OF CONTROLLING THE LIGHT SUM DOSE TO EFFECTIVELY INACTIVATE MICROORGANISMS IN BATCH REACTORS - The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor. | 05-16-2013 |
20130123699 | CONTINUITY CIRCUITS FOR DETECTING ACCESS DISCONNECTION - A monitor for an extracorporeal therapy access site is disclosed. The monitor includes a bandage atop or adjacent the access site and a sensor for monitoring the bandage. The bandage includes a layer of polymer that expands when wetted with blood. The expansion causes a break in continuity of the sensor, or in an alternate embodiment, causes a sensor to cease detecting a target. When the break occurs, the control circuit monitoring the bandage sends a signal that a break has occurred, and a remote monitor then takes appropriate action, such as ceasing therapy, sending an alert, or sounding an alarm. In another embodiment, connecting wires in a continuity circuit are held apart by a polymer that dissolves when contacted by blood. If a leak occurs and a small portion of the polymer dissolves, the wires make contact, thus detecting a blood leak. | 05-16-2013 |
20130123745 | INFUSION PUMP INCLUDING PAIN CONTROLLED ANALGESIC ("PCA") APPARATUS - An infusion pump includes: a housing, a pump actuator supported by the housing, electronics configured to control the pump actuator, a pain controlled analgesic (“PCA”) input device, a cord having a remote end connected to the PCA input device and a local end connected to the housing, a remote integrated circuit; and a local integrated circuit in communication with the electronics and the remote integrated circuit so as to provide operational information concerning the PCA input device to the electronics. | 05-16-2013 |
20130125808 | DEVICE TO INDICATE PRIMING OF AN INFUSION LINE - A priming indicator for a fluid infusion system includes a luer cap or other component of the infusion system having an indicator surface covered by a membrane. The membrane exhibits a first visual characteristic, such as being opaque, when dry and exhibits a second characteristic, such as becoming less opaque, when wet. Once the membrane becomes wet, indicia on the surface, which may be provided on a rod at least partially covered by the membrane, becomes visible, thereby indicating an intravenous tube to which the luer cap is secured has been primed or is nearly primed. The indicator may alternately be employed at an upstream end of an infusion set, such as at the port of a medical bag providing a supply of fluid, to indicate a low level of fluid in the medical bag. | 05-23-2013 |
20130129710 | HEMOSTATIC COMPOSITIONS - The invention discloses a method for producing a hemostatic composition comprising mixing a biocompatible polymer suitable for use in hemostasis and a genipin-type crosslinker, crosslinking said polymer by said genipin-type crosslinker to obtain a crosslinked biocompatible polymer, and finishing said crosslinks polymer to a pharmaceutically acceptable hemostatic composition, new hemostatic compositions and methods for using such compositions. | 05-23-2013 |
20130131581 | METHOD OF OPERATING A DIPSOSABLE PUMPING UNIT - A method of operating a disposable pumping unit includes enabling the disposable pumping unit to be loaded into a peritoneal dialysis hardware unit between a door and a housing of the hardware unit; structuring the disposable pumping unit to have a fluid pump receptacle, the fluid pump receptacle constructed and arranged to extend from both surfaces of the unit so as to fit within a first opening provided in the door and a second opening provided in the housing of the hardware unit; and enabling the disposable pumping unit to be guided into the hardware unit such that the fluid pump receptacle becomes aligned with the opposing first and second openings when the door is closed against the housing. | 05-23-2013 |
20130131582 | SYSTEMS AND METHODS FOR PERFORMING PERITONEAL DIALYSIS - A regenerative peritoneal dialysis system includes a dialysis fluid loop; a filter located in the dialysis fluid loop, a first portion of the dialysis fluid sent to the filter rejected by the filter and returned upstream of the filter, a second portion of the dialysis fluid sent to the filter forming permeate, the permeate being rich in urea; and a urea removing apparatus located in the dialysis fluid loop downstream from the filter to receive the permeate and absorb urea from the permeate. | 05-23-2013 |
20130131583 | TRANSFER SETS FOR THERAPY OPTIMIZATION - Transfer sets are disclosed in the present patent. The transfer set provides a connection between a source of peritoneal dialysis fluid and a patient for whom peritoneal dialysis has been prescribed. The transfer sets disclosed herein are smaller and provide a more compact and convenient device by which a dialysis patient controls the flow of dialysis fluid to and from the peritoneum of the patient. The devices are more compact and convenient because they include more convenient mechanisms for starting and stopping flow of the dialysis fluid. It is also easy to determine whether the mechanism is in a closed or open configuration by simply looking at the mechanism. | 05-23-2013 |
20130136732 | ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY - This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof. | 05-30-2013 |
20130138037 | MEDICAL FLUID MACHINE WITH SUPPLY AUTOCONNECTION - A medical fluid system including: fluid containers and a tube extending from same, each tube including a cap; a pumping cassette including port spikes; a medical fluid machine including: occluders; a shuttle configured to receive the tubes, wherein each tube is associated with one of the occluders; a driving mechanism translating the shuttle; a cap removal device between the cassette and the shuttle; and a control unit programmed to cause: (i) the occluders to pinch their tubes, (ii) cause the driving mechanism to translate the shuttle towards the fluid pumping cassette, the cap removal device engaging the tube caps, (iii) the driving mechanism to translate the shuttle away from the fluid pumping cassette and cap removal device, pulling the tube caps off of the tubes, and (iv) the driving mechanism to translate the shuttle back towards the fluid pumping cassette for the port spikes to spike the occluded tubes. | 05-30-2013 |
20130143238 | PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY - The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines. | 06-06-2013 |
20130150557 | METHOD FOR THE PURIFICATION OF RECOMBINANT BLOOD COAGULATION FACTOR IX ENRICHED IN SULFATED AND/OR PHOSPHORYLATED MOLECULES - The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules. | 06-13-2013 |
20130153478 | DIALYSIS SYSTEM INCLUDING PERISTALTIC TUBING PUMPING CASSETTE - A hemodialysis system includes: a peristaltic blood pump; a first peristaltic dialysate pump; a second peristaltic dialysate pump; and a fluid cassette including an upper portion and a lower portion, a blood pumping tube extending linearly from the upper portion to the lower portion, the blood pumping tube actuated by the peristaltic blood pump, a first dialysate pumping tube extending linearly from the upper portion to the lower portion, the first dialysate pumping tube actuated by the first dialysate pump, and a second dialysate pumping tube extending linearly from the upper portion to the lower portion, the second dialysate pumping tube actuated by the second dialysate pump. | 06-20-2013 |
20130153495 | SYSTEMS AND METHODS FOR PRIMING SORBENT-BASED HEMODIALYSIS USING DIALYSIS FLUID - A method for priming a hemodialysis treatment includes: providing a sorbent cartridge for cleaning spent dialysate fluid returning from a dialyzer; preparing a batch of dialysate in a quantity commensurate with being recycled through the sorbent cartridge multiple times; priming a dialysate circuit in fluid communication with the dialyzer using the batch of dialysate; and priming a blood circuit in fluid communication with the dialyzer using the batch of dialysate. | 06-20-2013 |
20130172269 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 07-04-2013 |
20130177601 | AQUEOUS COMPOSITIONS AND METHODS FOR BONE HEMOSTASIS - Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone. | 07-11-2013 |
20130177933 | Characterization of Subvisible Particles Using a Particle Analyzer - The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof. | 07-11-2013 |
20130186759 | HEMODIALYSIS AND PERITONEAL DIALYSIS SYSTEMS HAVING ELECTRODIALYSIS AND ELECTRODEIONIZATION CAPABILITIES - Systems and methods for hemodialysis or peritoneal dialysis having integrated electrodialysis and electrodeionization capabilities are provided. In an embodiment, the dialysis system includes a carbon source, a urease source, an ED/EDI unit. The carbon source, urease source, and/or the ED/EDI unit can be in the form of removable cartridges. | 07-25-2013 |
20130189678 | MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE - Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed. | 07-25-2013 |
20130190242 | Polymer-Von Willebrand Factor-Conjugates - The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF. | 07-25-2013 |
20130193041 | CONTROL OF A WATER DEVICE VIA A DIALYSIS MACHINE USER INTERFACE - A home medical device system includes a home therapy machine for performing a home therapy on a patient; a user interface operably connected to the home therapy machine, the user interface receiving operator inputs; a water treatment device in fluid communication with the home therapy machine; and a data connection between the home therapy machine and the water treatment device, wherein the home therapy machine transmits data via the connection to the water treatment device for control of the water treatment device, the data provided based on at least one of the operator inputs received via the user interface. | 08-01-2013 |
20130193073 | BALANCED FLOW DIALYSIS MACHINE - A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber. | 08-01-2013 |
20130195897 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 08-01-2013 |
20130197203 | Modified Polysaccharides for Conjugate Vaccines - The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease. | 08-01-2013 |
20130201482 | OPTICAL IMAGING SYSTEM WITH MULTIPLE IMAGING CHANNEL OPTICAL SENSING - An optical imaging system for use with an infusion tube including: at least one light source for emitting at least two of first, second, or third spectrums of light; an optics system including a single lens for receiving and transmitting at least two of the first spectrum light transmitted through a first portion of the chamber, the second spectrum light transmitted through a second portion of the chamber, or the third spectrum light transmitted through a third portion of the chamber. The system includes a sensor receiving the at least two of the spectrums from the lens and generating and transmitting data characterizing the at least two of the spectrums. The system includes a memory element storing computer readable instructions and a processor to execute the instructions to generate, using the data, at least two of first, second, or third images of the first, second, and third portions, respectively. | 08-08-2013 |
20130202550 | NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS - The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro. | 08-08-2013 |
20130204173 | RENAL THERAPY BLOOD CLEANSING SYSTEM WITH ISOLATION FEATURE - A renal therapy blood cleansing system is provided. The renal therapy blood cleansing system includes a blood filtering device in fluid communication with a blood circuit, a balance chamber configured to exchange like volumes of fresh and used therapy fluid with the blood filtering device, a first pump configured to pump fresh fluid to the balance chamber, a second pump positioned and arranged to receive used fluid from the blood filtering device, and a control scheme. The control scheme is programmed to isolate the blood filtering device from the second pump and deliver a volume of fresh fluid to the blood filtering device via the balance chamber while the second pump is isolated from the blood filtering device, so as to increase fluid volume within the blood circuit. | 08-08-2013 |
20130204192 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 08-08-2013 |